JP7042548B2 - Ｍａｇｌ阻害剤の結晶形態 - Google Patents

Ｍａｇｌ阻害剤の結晶形態 Download PDF

Info

Publication number
JP7042548B2
JP7042548B2 JP2019523672A JP2019523672A JP7042548B2 JP 7042548 B2 JP7042548 B2 JP 7042548B2 JP 2019523672 A JP2019523672 A JP 2019523672A JP 2019523672 A JP2019523672 A JP 2019523672A JP 7042548 B2 JP7042548 B2 JP 7042548B2
Authority
JP
Japan
Prior art keywords
compound
theta
crystalline
patient
hexafluoropropane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019523672A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019537596A5 (enExample
JP2019537596A (ja
Inventor
エー． グライス，シェリル
ケー． ジョーンズ，トッド
ジー． グリム，カート
ロレイン ブランクマン，ジャクリーン
ロドニー ビールス，チャニング
Original Assignee
ルンドベック ラ ホーヤ リサーチ センター，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ルンドベック ラ ホーヤ リサーチ センター，インク． filed Critical ルンドベック ラ ホーヤ リサーチ センター，インク．
Publication of JP2019537596A publication Critical patent/JP2019537596A/ja
Publication of JP2019537596A5 publication Critical patent/JP2019537596A5/ja
Priority to JP2022035398A priority Critical patent/JP7350117B2/ja
Application granted granted Critical
Publication of JP7042548B2 publication Critical patent/JP7042548B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019523672A 2016-11-16 2017-11-15 Ｍａｇｌ阻害剤の結晶形態 Expired - Fee Related JP7042548B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022035398A JP7350117B2 (ja) 2016-11-16 2022-03-08 Ｍａｇｌ阻害剤の結晶形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662423126P 2016-11-16 2016-11-16
US62/423,126 2016-11-16
PCT/US2017/061875 WO2018093953A1 (en) 2016-11-16 2017-11-15 Crystalline forms of a magl inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022035398A Division JP7350117B2 (ja) 2016-11-16 2022-03-08 Ｍａｇｌ阻害剤の結晶形態

Publications (3)

Publication Number Publication Date
JP2019537596A JP2019537596A (ja) 2019-12-26
JP2019537596A5 JP2019537596A5 (enExample) 2020-12-24
JP7042548B2 true JP7042548B2 (ja) 2022-03-28

Family

ID=62145805

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019523672A Expired - Fee Related JP7042548B2 (ja) 2016-11-16 2017-11-15 Ｍａｇｌ阻害剤の結晶形態
JP2022035398A Active JP7350117B2 (ja) 2016-11-16 2022-03-08 Ｍａｇｌ阻害剤の結晶形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022035398A Active JP7350117B2 (ja) 2016-11-16 2022-03-08 Ｍａｇｌ阻害剤の結晶形態

Country Status (38)

Country Link
US (2) US11142517B2 (enExample)
EP (2) EP3964503B1 (enExample)
JP (2) JP7042548B2 (enExample)
KR (1) KR102508739B1 (enExample)
CN (2) CN115093382A (enExample)
AU (1) AU2017361257B2 (enExample)
BR (1) BR112019010003A2 (enExample)
CA (1) CA3043610A1 (enExample)
CL (1) CL2019001340A1 (enExample)
CO (1) CO2019005045A2 (enExample)
CR (1) CR20190242A (enExample)
CY (2) CY1124870T1 (enExample)
DK (1) DK3541807T3 (enExample)
DO (1) DOP2019000120A (enExample)
EA (1) EA201991086A1 (enExample)
EC (1) ECSP19035171A (enExample)
ES (2) ES2900016T3 (enExample)
GE (2) GEAP202315091A (enExample)
HR (2) HRP20211863T1 (enExample)
HU (2) HUE064559T2 (enExample)
IL (1) IL266548A (enExample)
JO (1) JOP20190109B1 (enExample)
LT (1) LT3541807T (enExample)
MA (2) MA46866B1 (enExample)
MX (2) MX389459B (enExample)
MY (1) MY199386A (enExample)
NI (1) NI201900053A (enExample)
PE (1) PE20191239A1 (enExample)
PH (1) PH12019501068A1 (enExample)
PL (2) PL3541807T3 (enExample)
PT (1) PT3541807T (enExample)
RS (2) RS65016B1 (enExample)
SI (1) SI3541807T1 (enExample)
SM (2) SMT202100675T1 (enExample)
TN (1) TN2019000151A1 (enExample)
UA (1) UA124585C2 (enExample)
WO (1) WO2018093953A1 (enExample)
ZA (1) ZA201903093B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX350788B (es) 2012-01-06 2017-09-13 Abide Therapeutics Inc Compuestos de carbamato y preparación y uso de los mismos.
US10450302B2 (en) 2015-05-11 2019-10-22 Lundbeck La Jolla Research Center, Inc. Methods of treating inflammation or neuropathic pain
CN109996790B (zh) 2016-09-19 2023-05-16 H.隆德贝克有限公司 哌嗪氨基甲酸酯及其制备和使用方法
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
AU2017361254B2 (en) 2016-11-16 2021-09-23 H. Lundbeck A/S. Pharmaceutical formulations
PE20191239A1 (es) 2016-11-16 2019-09-16 Abide Therapeutics Inc Formas cristalinas de un inhibidor de magl
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
DK3630744T3 (da) 2017-05-23 2023-03-06 H Lundbeck As Pyrazol-magl-inhibitorer
UA126685C2 (uk) 2017-08-29 2023-01-11 Луннбек Ла-Холья Рісьоч Сенте, Інк. Сполуки, які є модуляторами magl, і способи їх отримання і застосування
EP3793547A4 (en) 2018-05-15 2021-11-17 H. Lundbeck A/S MAGL INHIBITORS
MX2021000549A (es) * 2018-07-19 2021-03-25 Pfizer Compuestos espiro heterociclicos como inhibidores de magl.
AU2019322538B2 (en) 2018-08-13 2021-09-30 F. Hoffmann-La Roche Ag New heterocyclic compounds as monoacylglycerol lipase inhibitors
PL3883936T3 (pl) 2018-11-22 2023-11-20 F. Hoffmann-La Roche Ag Nowe związki heterocykliczne
EP3914589A4 (en) * 2019-01-25 2022-11-30 H. Lundbeck A/S Methods of treating disease with magl inhibitors
WO2021097107A1 (en) * 2019-11-15 2021-05-20 Lundbeck La Jolla Research Center, Inc. Crystalline forms of a magl inhibitor
AU2021259496A1 (en) 2020-04-21 2022-11-10 H. Lundbeck A/S Synthesis of a monoacylglycerol lipase inhibitor
WO2023092079A1 (en) * 2021-11-19 2023-05-25 Bryant Cynthia W Use of cannabinoid compounds to treat gastrointestinal disorders
IL313987A (en) 2021-12-29 2024-08-01 Psy Therapeutics Inc Inhibiting monoacylglycerol lipase (magl)
IL316302A (en) 2022-05-04 2024-12-01 H Lundbeck As Crystalline form of 111333-hexafluoropro s-1-pyridazin-3-ylca azaspiro2.5octane-6- as a monoacylglycerol lipase inhibitor
CN117665187B (zh) * 2023-11-23 2024-08-16 宁波大红鹰药业股份有限公司 一种舒林酸中间体杂质的测定方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015508407A (ja) 2012-01-06 2015-03-19 アビデ セラピューティクス，インク． カルバメート化合物およびその製造および使用
WO2015164160A1 (en) 2014-04-21 2015-10-29 Merck Sharp & Dohme Corp. Pharmaceutical salts of an orexin receptor antagonist
WO2016183097A1 (en) 2015-05-11 2016-11-17 Abide Therapeutics, Inc. Methods of treating inflammation or neuropathic pain
WO2017143283A1 (en) 2016-02-19 2017-08-24 Abide Therapeutics, Inc. Radiolabeled monoacylglycerol lipase occupancy probe

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
AU1537292A (en) 1991-04-16 1992-11-17 Nippon Shinyaku Co. Ltd. Method of manufacturing solid dispersion
AU661080B2 (en) 1991-11-22 1995-07-13 Warner Chilcott Company, Llc Risedronate delayed-release compositions
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
KR100291362B1 (ko) 1992-10-16 2001-09-17 니뽄 신야쿠 가부시키가이샤 왁스매트릭스의제법
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
EP0827402A2 (en) 1995-05-17 1998-03-11 Cedars-Sinai Medical Center Compositions containing fatty acids for improving digestion and absorption in the small intestine
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
MXPA03005462A (es) 2000-12-18 2003-09-25 Novartis Ag Combinacion terapeutica de amlodipina y benazepril.
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
CA2476936A1 (en) 2002-02-20 2003-08-28 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
NZ560232A (en) 2005-02-25 2010-11-26 Hoffmann La Roche Tablets with improved drug substance dispersibility
ES2812250T3 (es) 2005-11-28 2021-03-16 Marinus Pharmaceuticals Inc Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas
EP1938804A1 (en) 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist
FR2938341A1 (fr) 2008-11-13 2010-05-14 Galderma Res & Dev Modulateurs de la monoglyceride lipase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
WO2010063802A1 (en) 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
CN101530399B (zh) 2009-04-15 2011-01-26 江苏中兴药业有限公司 一种水飞蓟宾固体自乳化片
US9567302B2 (en) 2012-03-19 2017-02-14 Abide Therapeutics, Inc. Carbamate compounds and of making and using same
US9321750B2 (en) 2012-04-20 2016-04-26 Innov17 Llc ROR modulators and their uses
SMT202500078T1 (it) 2012-11-02 2025-03-12 Vertex Pharma Composizioni farmaceutiche per il trattamento di malattie mediate da cftr
TW201446286A (zh) 2013-01-31 2014-12-16 Gilead Pharmasset Llc 抗病毒化合物之固態分散調製劑
US9551036B2 (en) 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
MX2015017961A (es) 2013-07-03 2016-10-14 Abide Therapeutics Inc Compuestos orgánicos pirrolo-pirrol carbamato y relacionados, composiciones farmacéuticas y usos médicos de los mismos.
US20150064252A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
CN103893258B (zh) 2013-12-05 2017-09-29 人福医药集团股份公司 含有广金钱草总黄酮的口服固体制剂及其应用
US10093630B2 (en) * 2014-05-21 2018-10-09 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
WO2016149401A2 (en) 2015-03-18 2016-09-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
PE20191239A1 (es) 2016-11-16 2019-09-16 Abide Therapeutics Inc Formas cristalinas de un inhibidor de magl
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
AU2017361254B2 (en) 2016-11-16 2021-09-23 H. Lundbeck A/S. Pharmaceutical formulations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015508407A (ja) 2012-01-06 2015-03-19 アビデ セラピューティクス，インク． カルバメート化合物およびその製造および使用
WO2015164160A1 (en) 2014-04-21 2015-10-29 Merck Sharp & Dohme Corp. Pharmaceutical salts of an orexin receptor antagonist
WO2016183097A1 (en) 2015-05-11 2016-11-17 Abide Therapeutics, Inc. Methods of treating inflammation or neuropathic pain
WO2017143283A1 (en) 2016-02-19 2017-08-24 Abide Therapeutics, Inc. Radiolabeled monoacylglycerol lipase occupancy probe

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AITIPAMULA, Srinivasulu et al.，Polymorphs, Salts, and Cocrystals: What's in a Name?，Crystal Growth and Design，2014年04月12日，vol.12，pp/2147-2152
STEPHEN M BERGE; LYLE D BIGHLEY; DONALD C MONKHOUSE，PHARMACEUTICAL SALTS，JOURNAL OF PHARMACEUTICAL SCIENCES，米国，AMERICAN PHARMACEUTICAL ASSOCIATION，1977年01月，VOL:66, NR:1，PAGE(S):1 - 19，http://dx.doi.org/10.1002/jps.2600660104
平山令明編，有機化合物結晶作製ハンドブック －原理とノウハウ－，丸善株式会社，2008年07月25日，p.57-84
芹澤一英，医薬品の多形現象と晶析の化学，2002年，p.273,278,305-17

Also Published As

Publication number Publication date
ES2900016T3 (es) 2022-03-15
JP2022084717A (ja) 2022-06-07
RU2019116689A3 (enExample) 2021-02-26
MA46866B1 (fr) 2021-11-30
WO2018093953A1 (en) 2018-05-24
SMT202300494T1 (it) 2024-01-10
SMT202100675T1 (it) 2022-01-10
MX389459B (es) 2025-03-20
CY1124870T1 (el) 2022-11-25
GEAP202315091A (en) 2023-05-10
MX2019005767A (es) 2019-12-05
EP3964503C0 (en) 2023-11-08
PL3541807T3 (pl) 2022-01-17
JOP20190109B1 (ar) 2022-09-15
EA201991086A1 (ru) 2019-11-29
CN110291083A (zh) 2019-09-27
CN110291083B (zh) 2022-06-17
RS65016B1 (sr) 2024-01-31
HRP20231697T1 (hr) 2024-03-15
AU2017361257A1 (en) 2019-05-30
RU2019116689A (ru) 2020-12-17
KR20190077561A (ko) 2019-07-03
US20200190063A1 (en) 2020-06-18
HRP20211863T1 (hr) 2022-03-04
CY1126586T1 (el) 2026-02-25
ES2966939T3 (es) 2024-04-25
RS62665B1 (sr) 2021-12-31
MA58133B1 (fr) 2024-02-29
PH12019501068A1 (en) 2019-08-19
UA124585C2 (uk) 2021-10-13
MA46866A (fr) 2021-06-02
MX2022000249A (es) 2022-02-03
ZA201903093B (en) 2020-11-25
DOP2019000120A (es) 2019-09-30
SI3541807T1 (sl) 2022-01-31
EP3541807A1 (en) 2019-09-25
HUE056973T2 (hu) 2022-04-28
TN2019000151A1 (en) 2020-10-05
HUE064559T2 (hu) 2024-03-28
EP3964503A1 (en) 2022-03-09
NZ753241A (en) 2021-06-25
ECSP19035171A (es) 2019-05-31
EP3964503B1 (en) 2023-11-08
GEP20237559B (en) 2023-10-25
BR112019010003A2 (pt) 2019-08-20
MY199386A (en) 2023-10-25
CR20190242A (es) 2019-07-09
CN115093382A (zh) 2022-09-23
US11993588B2 (en) 2024-05-28
CL2019001340A1 (es) 2019-10-04
EP3541807A4 (en) 2020-04-22
EP3541807B1 (en) 2021-09-29
KR102508739B1 (ko) 2023-03-09
CA3043610A1 (en) 2018-05-24
JP2019537596A (ja) 2019-12-26
AU2017361257B2 (en) 2022-02-10
PL3964503T3 (pl) 2024-04-02
JP7350117B2 (ja) 2023-09-25
LT3541807T (lt) 2021-12-27
DK3541807T3 (da) 2021-12-06
JOP20190109A1 (ar) 2019-05-09
PE20191239A1 (es) 2019-09-16
US11142517B2 (en) 2021-10-12
PT3541807T (pt) 2021-12-09
IL266548A (en) 2019-07-31
CO2019005045A2 (es) 2019-05-31
NI201900053A (es) 2019-10-30
US20220235037A1 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
JP7350117B2 (ja) Ｍａｇｌ阻害剤の結晶形態
US20240293324A1 (en) Solid dispersions comprising a sgc stimulator
JP2022511800A (ja) 痛風または高尿酸血症を処置または予防するための化合物の結晶形態
TW202330485A (zh) 用於治療或預防痛風或高尿酸血症之化合物的結晶形式
JP2025524598A (ja) Ｓ１ｐ受容体モジュレーターの結晶形態
RU2799564C2 (ru) Кристаллические формы ингибитора magl
HK40069310B (en) A crystalline form of a magl inhibitor
HK40069310A (en) A crystalline form of a magl inhibitor
AU2018325267B2 (en) Crystalline forms of compounds for preventing or treating sensory hair cell death
HK40009165A (en) A crystalline form of a magl inhibitor
HK40009165B (en) A crystalline form of a magl inhibitor
US9949964B2 (en) Tesofensine compositions
EA041551B1 (ru) Кристаллические формы ингибитора magl
WO2026085383A1 (en) Crystalline forms of an nlrp3 modulator
NZ753241B2 (en) Crystalline forms of a magl inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190730

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20190730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201111

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220214

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220311

R150 Certificate of patent or registration of utility model

Ref document number: 7042548

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees